Insu

liner

och

inje

ktio

nste

knik

, hu

r svå

rt k

an d

et v

ara?

Eller:Ingentingvarb

ättreförrnärd

etgällerd

iabe

tes.

Ande

rsFridÖrebrono

vembe

r201

9

Insu

lin d

etem

ir, s

can

d im

inje

ctio

nIns

ulin D

etemi

rMe

an P

rofile

s per

Adm

. Rou

teIn

sulin

Det

emir

(pm

ol/l)

e.g.

at t

ime

point

s lat

er th

an 2

40 m

inute

s for

the

i.v. a

dm. r

oute

ther

e is

one

or n

o va

lid m

easu

rem

ents

no m

arkin

gs o

ccur

on

the

figur

ea

mea

n co

ncen

tratio

n of

Insu

lin D

etem

ir. T

hus a

t tim

e po

ints w

here

Note

that

at le

ast t

wo m

easu

rem

ents

mus

t be

avail

able

to ca

lculat

eEa

ch m

ean

prof

ile b

ased

on

data

from

16

subje

ctsTr

ial ID

.: NN

304-

1320

Spad

ille A

pS (0

8FEB

02)

i.m.

i.v.

s.c.

0

500

1000

1500

2000

2500

3000

3500

4000

Elap

sed

Tim

e (h

ours

)0

36

912

1518

2124

Nov

o N

ordi

sk d

ata

on fi

le

Bild

från

inje

ktio

nsbr

osch

yr, N

ovo

1984

Bros

chyr

av

Nov

o om

inje

ktio

nste

knik

från

198

5

The

Palm

er In

ject

or 1

955-

1970

Cou

rtesy

Deb

bie

Hic

ks, L

ondo

n, U

K

Hel

inos

1954

-19

86

Hel

inos

195

4 -1

986

Nov

oPen

1985

Nov

o Fi

ne 8

mm

199

1

Bild

från

inje

ktio

nsbr

osch

yr, N

ovo

1984

CT

of th

igh,

nor

mal

-wei

ght a

dult

mal

e

CT

scan

of a

bdom

en, n

orm

al-w

eigh

t mal

e.

Whi

te d

ots

are

cont

rast

. 8 m

m n

eedl

e.

FITTER

RomeOctob

er20

15

Fitter

Attend

ees

(54coun

tries)

NB.

Additio

nalone

sin

ME,NAfricaandAsia

FITTER

Recommen

datio

nsadop

ted

into

LocalInsulinDe

liveryGu

idelines

(NB.

AllEurop

eandME,muchof

Asiaand

northe

rnS.Am

erica)

Publ

icer

ad 3

mar

s 20

18

Abs

orpt

ion

av d

irekt

verk

ande

in

sulin

anal

oger

•In

gen

skill

nad

i abs

orpt

ions

hast

ighe

t mel

lan

buk

och

lår.

•N

ågot

läng

re v

erka

n fr

ån lå

r.

Abso

rptio

n of

regu

lar i

nsul

in a

nd in

sulin

lis

pro2

Mea

n G

IR v

ersu

s tim

e of

all

treat

men

ts (n

= 1

2): R

egul

ar

insu

lin (0

.2 U

/kg;

A, i

nsul

in li

spro

(0.2

U/k

g; B

).

Braa

k EW

, et a

l. Diab

etes

Car

e.19

96;19

(12)

:1437

-144

0.

Abs

orpt

ion

av d

irekt

verk

ande

in

sulin

anal

oger

•In

gen

skill

nad

i abs

orpt

ions

hast

ighe

t mel

lan

buk

och

lår.

•N

ågot

läng

re v

erka

n fr

ån lå

r.

Abs

orpt

ion

av d

irekt

verk

ande

in

sulin

anal

oger

•In

gen

skill

nad

i abs

orpt

ions

hast

ighe

t mel

lan

buk

och

lår.

•N

ågot

läng

re v

erka

n fr

ån lå

r.•

Inge

n sk

illna

d i a

bsor

ptio

nsha

stig

het m

ella

n fe

tt o

ch

mus

kel,

bara

stu

dera

t i v

ila.

Abs

orpt

ion

av lå

ngve

rkan

de

insu

linan

alog

er•

Små

skill

nade

r i a

bsor

ptio

n m

ella

n lå

r och

buk

(någ

ot

lång

sam

mar

e fr

ån b

uk fö

r gla

rgin

)•

Stor

ski

llnad

i ab

sorp

tions

hast

ighe

t mel

lan

fett

och

m

uske

l.

Insu

lin d

etem

ir, s

c an

d im

inje

ctio

nIns

ulin D

etemi

rMe

an P

rofile

s per

Adm

. Rou

teIn

sulin

Det

emir

(pm

ol/l)

e.g.

at t

ime

point

s lat

er th

an 2

40 m

inute

s for

the

i.v. a

dm. r

oute

ther

e is

one

or n

o va

lid m

easu

rem

ents

no m

arkin

gs o

ccur

on

the

figur

ea

mea

n co

ncen

tratio

n of

Insu

lin D

etem

ir. T

hus a

t tim

e po

ints w

here

Note

that

at le

ast t

wo m

easu

rem

ents

mus

t be

avail

able

to ca

lculat

eEa

ch m

ean

prof

ile b

ased

on

data

from

16

subje

ctsTr

ial ID

.: NN

304-

1320

Spad

ille A

pS (0

8FEB

02)

i.m.

i.v.

s.c.

0

500

1000

1500

2000

2500

3000

3500

4000

Elap

sed

Tim

e (h

ours

)0

36

912

1518

2124

Nov

o N

ordi

sk d

ata

on fi

le

Abs

orpt

ion

av H

uman

insu

liner

•Sn

abba

re a

bsor

ptio

n fr

ån m

uske

l jäm

fört

fett

.•

Snab

bare

abs

orpt

ion

från

buk

jäm

fört

lår.

Inje

ktio

nsdj

up h

ar s

anno

likt i

ngen

be

tyde

lse

(två

stu

dier

)

Inje

ctio

n D

epth

and

Insu

lin A

bsor

ptio

n

•12

5 I-la

belle

d sh

ort a

ctin

g in

sulin

was

inje

cted

( 5

units

eac

h pa

tient

)•

Rad

ioac

tivity

dec

reas

ed b

y in

sulin

ab

sorp

tion

(in %

)•

One

def

ined

inje

ctio

n si

te w

as c

hose

n fo

r eac

h ab

omen

and

thig

h•

2 in

ject

ion

dept

hs, c

ontro

lled

by

ultra

soun

d:A)

3mm

bel

ow th

e sk

in s

urfa

ceB)

2mm

abo

ve th

e m

uscl

e fa

cies

Frid

etal.,Intraregiona

lDifferen

cesin

theAb

sorptio

nof

Unm

odified

Insulin

from

theAb

dominalWall_Diab

eticMed

icine19

92;9

;236

239

InjectionDe

pthB)

[from

skinsurfa

ceinmm]:

Abdo

men

92/

153

Thigh

71/

143

A)

B)

3mm

2mm

Inje

ctio

n D

epth

and

Insu

lin A

bsor

ptio

n

No

influ

ence

of t

he in

ject

ion

dept

h on

the

kine

tics

of in

sulin

abs

orpt

ion

has

been

sho

wn

in th

e st

udy.

405060708090100

60 m

in12

0 m

in17

5 m

in

Thig

h - D

eep

Inje

ctio

nTh

igh

- Sup

erfic

ial I

njec

tion

Abdo

men

- D

eep

Inje

ctio

nAb

dom

en -

Supe

rfic

ial I

njec

tion

JDiabe

tesS

ciTechno

l.2015

Jul;9(4):8

2430

Insu

liner

med

kon

cent

ratio

n >

100

E/m

L

•Gla

rgin

(Tou

jeo)

300

E/m

L•D

eglu

dec

(Tre

siba

) 200

E/m

L•L

ispr

o(H

umal

og) 2

00 E

/mL

Deg

lude

c10

0 vs

200

E/m

L

Insu

lin li

spro

(Hum

alog

)

FITTER

isascientificcongress

spon

soredby

Nee

dle

reus

e

FITTER

isascientificcongress

spon

soredby

Reu

se P

erce

ntag

es b

y C

ount

ry (1

)Co

untry

Yes

No

USA

18.4

81.6

Canada

38.7

61.3

Russia

90.3

9.7

SouthAfrica

96.7

3.3

Nethe

rland

s18

.581

.5

Belgium

86.7

13.3

France

20.1

79.9

Spain

37.7

62.3

Italy

15.5

84.5

Switzerland

52.7

47.3

Austria

71.9

28.1

UK

26.1

73.9

Sverige

49.0

51.0

REUSE

FITTER

isascientificcongress

spon

soredby

Res

ults

2tim

es35tim

es610

times

>10tim

es

Nurse

Reported

31.2

41.0

15.4

12.4

PatientReported

30.7

39.7

16.0

13.6

Sverige

1245

1231

FITTER

isascientificcongress

spon

soredby

Why

do

they

reus

e th

e pe

n ne

edle

s?

42

Reason

s%

Sver

ige

BecauseIdidno

thaveanothe

rpen

need

leavailable

9.2

2

Tosave

mon

ey23

.32

Toprevente

xcesswaste

(enviro

nmen

tal

concern)

6.8

4

Forcon

venien

ce41

.278

FITTER

isascientificcongress

spon

soredby

How

ofte

n do

es th

e nu

rse

or

doct

or e

xam

ine

inje

ctio

n si

tes?

43

Freq

uency

%

Routinelyeveryvisit.

28.3

Onceayear

12.6

OnlyifIcom

plainof

aprob

lem

atasite

20.2

Ican’tremem

berm

ysites

ever

beingchecked

38.9

FITTER

isascientificcongress

spon

soredby

Lipo

Perc

enta

ges

by C

ount

ry (1

)Co

untry

YES

NO

Num

ber

USA

6.9

93.1

304

Canada

28.8

71.2

281

Russia

24.0

76.0

104

SouthAfrica

34.8

65.2

155

Nethe

rland

s40

.859

.276

Belgium

33.1

66.9

136

France

36.2

63.8

224

Spain

60.2

39.8

196

Italy

39.4

60.6

310

Switzerland

29.1

70.9

55

Austria

28.4

71.6

95

Argentina

65.3

34.7

72

Swed

en56

.443

.610

144

6en

kla

råd

om in

sulin

inje

ktio

ner

•Det

finn

s in

ga m

edic

insk

a sk

äl a

tt a

nvän

da lä

ngre

nål

än

4 m

m•I

njic

era

aldr

ig i

mus

kel.

•Mod

erna

insu

linan

alog

er ta

s up

p i s

tort

set

t lik

a fr

ån fe

ttvä

ven

på

alla

inje

ktio

nsst

älle

n.•N

PH-i

nsul

in o

ch m

ixin

sulin

erge

s he

lst i

buk

en p

å m

orgo

nen

och

bake

n/lå

ret p

å kv

älle

n.•N

ytt s

tälle

var

je g

ång.

Reg

elbu

nden

und

ersö

knin

g av

in

jekt

ions

stäl

len.

•Anv

änd

högr

e in

sulin

konc

entr

atio

n nä

r det

är m

öjlig

t.